Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b
Induction and Nilotinib or Pegylated Interferon-alpha2b
Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic
Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of
the Tiger (CML V)-Study

a 2018

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study

HOCHHAUS, Andreas; Susanne SAUSSELE; Gabriela M BAERLOCHER; Tim H BRUEMMENDORF; Andreas BURCHERT et al.

Základní údaje

Originální název

Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study

Autoři

Vydání

2018

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

TIGER

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/18:00143431

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1182/blood-2018-99-112119

UT WoS

000454837601169

Klíčová slova česky

TIGER STUDY; nilotinib (NIL); monotherapy; chronic myeloid leukemia (CML)

Klíčová slova anglicky

TIGER STUDY; nilotinib (NIL); monotherapy; chronic myeloid leukemia (CML)

Štítky

Excelence Science, Klinické hodnocení, RIV, user, článek v časopise

Změněno: 9. 4. 2026 12:54, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: The TIGER (CML V)-study (NCT01657604) is a multicenter, randomized phase III trial to evaluate efficacy and tolerability of nilotinib (NIL) 2*300mg/d monotherapy vs NIL 2*300mg/d + pegylated interferon alpha2b (Peg-IFN) and the option to discontinue therapy after Peg-IFN maintenance as first line therapy for chronic myeloid leukemia (CML) patients in chronic phase.

Návaznosti

90090, velká výzkumná infrastruktura

Název: CZECRIN II

Citovat

HOCHHAUS, Andreas; Susanne SAUSSELE; Gabriela M BAERLOCHER; Tim H BRUEMMENDORF; Andreas BURCHERT; La Rosee PAUL; Joerg HASFORD; Ruediger HEHLMANN; Dominik HEIM; Stefan W KRAUSE; Le Coutre PHILIPP; Dietger NIEDERWIESER; Jiří MAYER; Thoralf LANGE; Mathias HAENEL; Frank STEGELMANN; Arthur GIL; Thomas ERNST; Christian FABISCH a Markus PFIRRMANN. Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study. 2018. Dostupné z: https://doi.org/10.1182/blood-2018-99-112119.

@proceedings{2548381,
   author = {Hochhaus, Andreas and Saussele, Susanne and Baerlocher, Gabriela M and Bruemmendorf, Tim H and Burchert, Andreas and Paul, La Rosee and Hasford, Joerg and Hehlmann, Ruediger and Heim, Dominik and Krause, Stefan W and Philipp, Le Coutre and Niederwieser, Dietger and Mayer, Jiří and Lange, Thoralf and Haenel, Mathias and Stegelmann, Frank and Gil, Arthur and Ernst, Thomas and Fabisch, Christian and Pfirrmann, Markus},
   doi = {https://doi.org/10.1182/blood-2018-99-112119},
   keywords = {TIGER STUDY; nilotinib (NIL); monotherapy; chronic myeloid leukemia (CML)},
   language = {eng},
   title = {Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study},
   url = {https://www.sciencedirect.com/science/article/pii/S0006497119365097?pes=vor&utm_source=clarivate&getft_integrator=clarivate},
   year = {2018}
}

TY  - CONF
ID  - 2548381
AU  - Hochhaus, Andreas - Saussele, Susanne - Baerlocher, Gabriela M - Bruemmendorf, Tim H - Burchert, Andreas - Paul, La Rosee - Hasford, Joerg - Hehlmann, Ruediger - Heim, Dominik - Krause, Stefan W - Philipp, Le Coutre - Niederwieser, Dietger - Mayer, Jiří - Lange, Thoralf - Haenel, Mathias - Stegelmann, Frank - Gil, Arthur - Ernst, Thomas - Fabisch, Christian - Pfirrmann, Markus
PY  - 2018
TI  - Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study
KW  - TIGER STUDY
KW  - nilotinib (NIL)
KW  - monotherapy
KW  - chronic myeloid leukemia (CML)
UR  - https://www.sciencedirect.com/science/article/pii/S0006497119365097?pes=vor&utm_source=clarivate&getft_integrator=clarivate
N2  - Introduction: The TIGER (CML V)-study (NCT01657604) is a multicenter, randomized phase III trial to evaluate efficacy and tolerability of nilotinib (NIL) 2*300mg/d monotherapy vs NIL 2*300mg/d + pegylated interferon alpha2b (Peg-IFN) and the option to discontinue therapy after Peg-IFN maintenance as first line therapy for chronic myeloid leukemia (CML) patients in chronic phase.
ER  -

HOCHHAUS, Andreas; Susanne SAUSSELE; Gabriela M BAERLOCHER; Tim H BRUEMMENDORF; Andreas BURCHERT; La Rosee PAUL; Joerg HASFORD; Ruediger HEHLMANN; Dominik HEIM; Stefan W KRAUSE; Le Coutre PHILIPP; Dietger NIEDERWIESER; Jiří MAYER; Thoralf LANGE; Mathias HAENEL; Frank STEGELMANN; Arthur GIL; Thomas ERNST; Christian FABISCH a Markus PFIRRMANN. \textit{Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study}. 2018. Dostupné z: https://doi.org/10.1182/blood-2018-99-112119.

Přehled o publikaci